Abstract
Integration of genetic, social network, and spatial data has the potential to improve understanding of transmission dynamics in established HCV epidemics. Sequence data were analyzed from 63 viremic people who inject drugs recruited in the Boston area through chain referral or time-location sampling. HCV subtype 1a was most prevalent (57.1%), followed by subtype 3a (33.9%). The phylogenetic distances between sequences were no shorter comparing individuals within versus across networks, nor by location or time of first injection. Social and spatial networks, while interesting, may be too ephemeral to inform transmission dynamics when the date and location of infection are indeterminate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was funded by an internal grant from Tufts University (no number assigned) with additional funding from the Providence-Boston Center for AIDS Research (PI: Stopka), through Grant Number P30AI042853 from the National Institute of Allergy and Infectious Diseases. Support for Dr. Heimer was provided through Grant Number R01DA030420 from the National Institute on Drug Abuse. Initials of the authors who received each award TJS for Tufts Institute for Innovation (TII), which is now defunct The TII award did not have a grant number internal mechanism The full name of each funder See above and below URL of each funder website TII no longer exists no website Additional support from the Providence-Boston CFAR: https://cfar.med.brown.edu/ P30AI042853 from NIAiD https://www.niaid.nih.gov/ RH received support through R01DA030420 from NIDA. NIDA: https://nida.nih.gov/ Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? No The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
?The study protocol was approved by the Tufts University Institutional Review Board? Tufts IRB #: 11825
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The data will be uploaded to a public repository upon acceptance of the manuscript.